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ABSTRACT
Background: In Indonesia, phytoestrogens can be found in the market as supplement to resolve climacteric complaint and
osteoporosis. This phytoestrogens has not been proven scientifically to have benefit in overcoming the climacteric complaints and
osteoporosis in menopausal women. Therefore, it is important to have clinical test searching data for knowing the increase of bone
mineral density (BMD).
Methods: The design was comparison clinical test in the form of “add on” with double blind in Hospital of Mohammad Hoesin
Palembang started in August 2010 until February 2011 putting subjects into fitoestrogen and placebo groups randomly. T-score of
spine and femur were measured using done densitometry before and after 6 months supplementation.
Results: In the beginning of study, it was found that the average of spine T-score in the group of phytoestrogens was
-1.455±0.264 after 6 months it increased to -1.295±0.223 with change 0.160±0.153 (p=0.001).Whereas in placebo group the average
of spine T-score at the beginning of the study was -1.295±0.223 becoming -1.560±0.414 with decrease of -0.100±0.273 (p=0.118).
Femur T-score level, of phytoestrogens group at the beginning of the study was -1.415±0.215, after 6 months it became -1.270±0.141
with change of 0.145±0.170 (p=0.001). In placebo group, the average of femur T-score was -1.475±0.202 becoming -1.595±0.421
with of decrease -0.120±0.33 (p=0.124). The status of spine and femur T-score BMD both in, phytoestrogens and placebo group was
osteopenia at the beginning of the study. After 6 months, spine T-score in phytoestrogens group did not change, and in placebo
group, 2 subject showed osteoporosis with spine T-score and femur T-score -2.7 and -2.75(±0.212).
Conclusions: The administration of phytoestrogens is able to maintain bone mineral density and prevent the occurrence of
osteoporosis.
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ABSTRAK
Fitoestrogen genistein dan black cohosh dan penanda BMD pada perempuan menopause
Latar belakang: Di Indonesia, fitoestrogen beredar di pasaran sebagai suplemen untuk mengatasi keluhan klimakterik dan
osteoporosis. Fitoestrogen ini belum terbukti secara ilmiah bermanfaat untuk mengatasi keluhan klimakterik maupun osteoporosis
pada perempuan menopause. Oleh karena itu uji klinik ini dilakukan untuk mencari data guna mengetahui meningkatnya gambaran
BMD.
Metode: Desain adalah uji klinik berpembanding dalam bentuk add on, secara tersamar ganda di RS Dr. Mohammad Hoesin
Palembang bulan Agustus 2010 sampai dengan Februari 2011 pada subyek yang dibagi dalam kelompok fitoestrogen dan placebo
secara acak. Variabel yang diukur adalah skor T tulang vertebra dan femur menggunakan bone densitometer sebelum dan setelah 6
bulan mendapat suplemen.
Hasil: Pada awal penelitian rerata T-skor tulang belakang kelompok fitoestrogen -1,455±0,264 setelah 6 bulan menjadi
-1,295±0,223 dengan perubahan 0,160 ± 0,153 (p=0,001). Sedangkan kelompok plasebo rerata T-skor tulang belakang pada awal
penelitian -1,295±0,223 menjadi -1,560±0,414 dengan penurunan -0,100±0,273 (p=0,118). Pada kadar T-skor femur, di awal
penelitian kelompok fitoestrogen -1,415±0,215 setelah 6 bulan menjadi -1,270±0,141 dengan besaran perubahan 0,145±0,170
(p=0,001). Pada kelompok plasebo rerata T-skor femur pada awal penelitian -1,475±0,202 menjadi -1,595±0,421 dengan perubahan
-0,120±0,33 (p=0,124). Status BMD T-skor tulang belakang dan femur di awal penelitian, kelompok fitoestrogen dan kelompok
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plasebo adalah osteopeni. Setelah 6 bulan kemudian, pada
kelompok fitoestrogen tidak terdapat perubahan status BMD
sedangkan pada kelompok plasebo terdapat 2 orang yang
densitas mineral tulangnya mengalami perubahan menjadi
osteoporosis dengan rerata T-skor tulang  belakang -2,70
dan T-skor femur -2,750 ± 0,212.
Simpulan: Pemberian fitoestrogen dapat mempertahankan
densitas mineral tulang dan mencegah terjadinya osteo-
porosis.
BACKGROUND
The best choice and standard medication for climacteric
complaint and osteoporosis is hormonal therapy
(estrogen + progesterone/estrogen) based on the cause,
that is the lack of estrogen hormone. In 2004, WHI
(women’s health initiative) stated, based on its research,
that hormonal therapy on menopause women increased
the risk of breast cancer. This statement decreased the
hormonal therapy users, and women altered to
supplement use including fitoestrogen for therapy of
climacteric complaint and osteoporosis. However, has
not had enough study proofs about the benefit of
fitoestrogen.1
In Indonesia, phytoestrogens strongly circulates in
market with category of supplement and has been used
by people to overcome climacteric complaint and
osteoporosis. This phytoestrogens has not been proven
scientifically to have benefit in overcoming the
climacteric complaints and osteoporosis in menopausal
women.
This study chose the age of 45-55 years old age estrogen
hormone production decrease, is an ideal age to prevent
the occurrence of osteoporosis. Therefore, it is
important to know and analyze effect of fitoestrogen
supplementation on BMD.
METHOD
This study was comparing clinical test in the form of
add on with double blind. The proposal was approved
by Bioethics and Humanities Unit of Medical Faculty of
Sriwijaya University. Number of samples was
calculated using the following equation :
n =      ,2
)1(1 f
PcPt
PcPcPtPt 


The subjects in this study were women with menopausal
age. The examination of BMD marker was done twice,
before and after 6 months of administration of
fitoestrogen genistein and black cohosh. Placebo was
given in the same form. The examination of BMD
marker was executed in YK. Madira Palembang. The
success parameter in this research was to maintain bone
mineral density of spine and femur.
Study variables include: demographic characteristics
(age, age of menars, education, parity and old menars),
independent variables (densitometry of spine and
femur), and the dependent variable (fitoestrogen).
Fitoestrogen given were 15 mg soya genistein + 3 mg
black cohosh twice daily.
Data collection was done by way of each participant
who filled the inclusion and exclusion criteria would
accept identification number and card as research
subject. All research results of anamnesis, physical
examination, laboratory, the result of spine T-score and
femur T-score was noted in research sheets. The
examination of bone mineral density was done twice
before and after 6 months of giving phytoestrogens in
YK. Madira Palembang. Data were analyzed using chi-
square and T-test.
RESULTS
Forty subjects were recervited starting August 2010
until February 2011. Subjects into 2 groups, namely
phytoestrogens group and placebo group which were
randomly assigned.
General characteristic distribution of subject is
completely figured out in Table 1.
Table 1 shows no significant difference on age between
both group. Similarly, for education of graduate (S1) in
phytoestrogens group was 8 subjects (40.0%) and in
placebo group was 10 subjects (50.0%) with p=0.810.
Only 11 subjects (55.0%) and 15 subjects (65.0%) in
both group that can be evaluated at the end of the study.
It was found that the average of menars age in
phytoestrogens group was 13.25±1.25 years while the
placebo group was 13.05±1.35 years. Statistically there
was no significant difference in menars age in the both
groups (p=0.631). Menopause duration experienced by
study subjects, it in phytoestrogens group was
36.60±14.29 month while in placebo was 40.20±16.64
month. Statistically there was not significant difference
in menopause duration in the both groups (p=0.468).
Characteristic of menars age and menopause duration of
research group can completely be seen in Table 2.
In the beginning of study, it was found that the average
of spine T-score in the group of phytoestrogens was
-1.455±0.264 and it increased to -1.295±0.223 with
change amount of 0.160±0.153 and had significant
correlation (p=0.001). Whereas in placebo group it had
decrease where the average of spine T-score in research
onset was -1.295±0.223 becoming -1.560±0.414 with
decrease amount of -0.100±0.273 and there was not
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significant correlation (p=0.118). According to
statistical analysis of t-test, there was significant
difference between average change of spine T-score in
phytoestrogens group and placebo group (p=0.001). The
average of spine T-score of the groups both can
completely be seen in Table 3.
Table 1. General characteristic of research subjects
General characteristic Phytoestrogens Placebon % n %
Age (year)
45 - 50 9 45.0 5 35.0
51 - 55 11 55.0 15 65.0
Education
Elementary school 4 20.0 3 15.0
Junior high school 2 10.0 3 15.0
Senior high school 6 30.0 4 20.0
Graduate (S1) 8 40.0 10 50.0
Elementary school 4 20.0 3 15.0
Junior high school 2 10.0 3 15.0
Senior high school 6 30.0 4 20.0
Graduate (S1) 8 40.0 10 50.0
Job
Housewife 11 55.0 9 45.0
Nurse 2 10.0 4 20.0
Midwife 4 20.0 5 25.0
Seller 1 5.0 2 10.0
Labor 2 10.0 0 0.0
Housewife 11 55.0 9 45.0
Body Mass Index
<18,5 4 20.0 1 5.0
18,5 - 27 14 70.0 17 85.2
>27 2 10.0 2 10.0
Parity
2 6 30.0 4 20.0
3 8 40.0 5 25.0
4 2 10.0 4 20.0
5 2 10.0 5 25.0
6 2 10.0 2 10.0
Total 20 100.0 20 100.0
Table 2. Characteristic of menarche and menopause duration of subjects
Variable Phytoestrogens(average±SD)
Placebo
(average±SD) p
Menarche (year) 13.25 ± 1.25 13.05 ± 1.35 0.631
Menopause duration (month) 36.60 ± 14.29 40.20 ± 16.64 0.468
t-test SD = standard deviation
Table 3. T-score result in spine examination of research subjects
Examination Fitoestrogen(average±SD) p*
Plasebo
(average±SD) p* p*
Research onset -1.455 ± 0.264 0.001a -1.460 ± 0.223 0.118b 0.949
c
After 6 month -1.295 ± 0.223 -1.560 ± 0.414 0.016d
The change 0.160 ± 0.153 -0.100 ± 0.273 0.001e
* t-test SD = standard deviation
a. Natrium : Phytoestrogens group: Onset: After d. After: Phytoestrogens group: placebo group
b. Placebo group: Onset: After e. Change: Phytoestrogens group: placebo group
c. Onset: Phytoestrogens group: placebo group
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Table 4. T-score result in femur examination of research subjects
Examination Phytoestrogens(average±SD) p*
Placebo
(average±SD) p* p*
Research onset -1.415 ± 0.215 0.001a -1.475 ± 0.202 0.124b 0.370
c
After 6 months -1.270 ± 0.141 -1.595 ± 0.421 0.002d
The change 0.145 ± 0.170 -0.120 ± 0.333 0.004e
* t-test SD = standard deviation
a. Natrium phytoestrogens group: Onset: After d. After: Phytoestrogens group: placebo group
b. Placebo group: Onset: After e. Change: Phytoestrogens group: placebo group
c. Onset: Phytoestrogens group: placebo group
Table 5. Bone mineral density status in spine and femur
BMD status Phytoestrogens (average±SD) Placebo (average±SD)
Research onset
Spine :
Osteopenia 20(-1.455 ± 0.264) 20(-1.460 ± 0.223)
After 6 months
Osteopenia 20(-1.295 ± 0.223) 18(-1.433 ± 0.149)
Osteoporosis
Femur :
Osteopenia
After 6 months
Osteopenia
Osteoporosis
0(0)
20(-1.415 ± 0.215)
20(-1.270 ± 0.141)
0(0)
2(-2.700 ± 0.000)
20(-1.475 ± 0.202)
18(-1.467 ± 0.145)
2(-2.750 ± 0.212)
The examination result of subject’s femur was not far
different with examination on spine, in the beginning of
research, the average of femur T-score in phyto-
estrogens group was -1.415±0.215 and it had increase to
-1.270±0.141 with change amount of  0.145±0.170 with
p=0.001. In placebo group it had decrease where the
average of femur T-score in research onset was
-1.475±0.202 becoming -1.595±0.421 with decrease
amount of -0.120±0.33 and there was not significant
correlation (p=0.124). Based on statistical analysis of
t-test, there was significant difference between average
change of femur T-score in phytoestrogens group with
placebo group (p=0.001). The average of femur T-score
in the two groups can completely be seen in Table 4.
It can be seen in Table 5, BMD status of spine and
femur T-score in research onset, phytoestrogens and
placebo group was osteopenia. After 6 months, in
phytoestrogens group there was not change of BMD
status and in placebo group there were 2 persons whose
bone mineral density had change becoming osteoporosis
with the average of spine T-score was 2.70 and femur
T-score was -2.750±0.212.
DISCUSSION
Characteristics of subject
The age interval of research subject in phytoestrogens
and placebo group largely constituted in interval of 51-
55 years old, namely 11 subjects (55.0%) in phyto-
estrogens group and placebo group was 15 subjects
(65.0%). The average of age in this research is almost
same with the average of subject age in research done
by Tice JA, et al. (52.3 year), William RE, et al. had
interval of 50-54 years with amount of 41% and
Suzanne C, et al. (48-63 years).
General characteristic in this research is not far different
with research performed by Suzanne C, et al. which
reported that body mass index was low and high energy
diet, calcium, phosphor, vegetable protein, soybean
protein, and fresh fruits. Elizabeth, et al. reported that
there was significant correlation on high parity with
increase of hip BMD at old woman and largely with
higher body mass index.
Menarche and menopause duration
From this study result it was got the average of menars
age in phytoestrogens group was 13.25±1.25 years
whereas in placebo group was 13.05±1.35 years. For
duration variable of menopause experienced by research
subject, it was gained that the average in phytoestrogen
group was 36.60±14.29 month and placebo group was
40.20±16.64 months. In the study of Suzanne C, et al. it
was reported that the average of menopause duration
was 4.6±2.8 years with interval of menarche age from
12.5 years.
Spine and femur T-score
Rosen HN (2003) in Australia reported that the change
of bone marker may benefit on osteoporosis in
estimating the risk of lack of bone loss in future, the risk
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of fracture in future, or to observe the effectiveness of
anti-resorption therapy. Some women (10-50%) are
getting bone loss when they still received anti-
resorption therapy and the patients need alternative
therapy or additional therapy. This point shows that in
experiment some women with significant growth of
BMD have showed the substansial decrease in the
possible risk of backbone fracture, so they recommend
counting BMD in baseline after 1 or 2 years of therapy.
In this study it was found that the status of bone mineral
density of research subject in phytoestrogens group and
placebo group was osteopenia. After 6 months later, in
phytoestrogens group there was not change of bone
mineral density status whereas in placebo group there
were 2 people experiencing the change of bone mineral
density to be osteoporosis. It shows that phytoestrogens
influence the bone metabolism in maintaining bone
density to prevent the occurrence of osteoporosis.
Our study result shows that after 6 months, there was
higher change of spine T-score level in phytoestrogens
than placebo group, namely 0.160±0.153 in the ratio of
0.100±0.273 and has significant difference (p=0.001). In
femur T-score in phytoestrogens group is higher than in
placebo group, viz. 0.145±0.170 in the ratio of
-0.120±0.333 and has significant difference (p=0.001).
It is same with the research performed by Mei, et al. in
Hongkong, which showed that post-menopause woman
with high isoflavon diet showed high BMD result in
spine and hip area. High phytoestrogens diet helps to
avoid the occurrence of secondary hyperparathyroidism
caused by estrogen decrease which further descends
bone turn over on women with post menopause.
One study by using control placebo involving 66
women with post menopause showed the improvement
in bone density. The patient was divided into 3 groups
and got isoflavon of 56 mg/day, 90 mg/day and non-fat
milk. Vertebra bone density was measured by using
dual x-ray energy. In the group which got isoflavon of
90 mg/day showed significant bone density increase of
2% in vertebra L1-L4. Another research which involved
69 women with perimenopause showed that there was
no decrease of bone density in the group which got
isoflavon 80 mg/day during 24 weeks compared with
control group. Tsourounis C reported that alternative
hormonal therapy could increase density of vertebra
bone of 3.5-5% in women with post menopause. Even
though phytoestrogens and ipriflavon seemed less
potent compared with estrogen, they remained to offer
protection effect in vertebra and radius bone density.
Clinical experiment, with period of more than 24 weeks,
still needs to perform for scoring phytoestrogens role
and phytoestrogens amount required to give protection
on osteoporosis. So far, phytoestrogens still constitutes
option to inhibit osteoporosis process in women with
peri or post menopause who can’t be given alternative
hormonal therapy or for those who refuse alternative
hormonal therapy.
Some studies concluded that fitoestrogen effect in bone
metabolism was caused by phytoestrogens binding in
receptor of estrogen β constituting in bone, which would
influence bone mass through inhibition of osteoclast
activity and increase of osteoblast activity, as well as the
increase of calcitonin secretion which would inhibit
activity of parathyroid hormone (PTH) towards bone
resorption process. Estrogen increases activity of 1-α
hydrocylase in kidney which changes non active
vitamin D to be active in order that calcium resorption
via intestine increases. In perimenopausal women,
administration of isoflavon more than 90 mg/day during
24 months increase bone mineral density in lumbar
vertebrae and femoral collum, as well as prevent the
occurrence of osteoporosis.
CONCLUSION
BMD status of spine and femur T-score in study at the
beginning of the study in both groups were osteopenia.
After 6 months, in phytoestrogens group there was no
change of BMD status while in placebo group there
were 2 persons whose bone mineral density change to
be osteoporosic with the average of spine T-score of
-2.70 and femur T-score of -2.750±0.212. Therefore,
phytoestrogens administration has influenced in
maintaining bone mineral density to prevent the
occurrence of osteoporosis.
SUGGESTION
Further study is required by combining phytoestrogens
and meal pattern to see whether there will be a different
result.
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